Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets
Background: The major facilitator superfamily glucose transporters (GLUTs), encoded by solute carrier 2A (SLC2A) genes, mediate the transmembrane movement and uptake of glucose. To satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues. Multiple di...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S240584402405686X |
| _version_ | 1827261754306985984 |
|---|---|
| author | Yating Liu Xinyu Li Jie Yang Shanshan Chen Changyu Zhu Yijun Shi Shoutao Dang Weitao Zhang Wei Li |
| author_facet | Yating Liu Xinyu Li Jie Yang Shanshan Chen Changyu Zhu Yijun Shi Shoutao Dang Weitao Zhang Wei Li |
| author_sort | Yating Liu |
| collection | DOAJ |
| description | Background: The major facilitator superfamily glucose transporters (GLUTs), encoded by solute carrier 2A (SLC2A) genes, mediate the transmembrane movement and uptake of glucose. To satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues. Multiple diseases, including cancer, have been associated with GLUTs. Nevertheless, not much research has been done on the functions of SLC2As in pan-cancer prognosis or their clinical treatment potential. Methods: The SLC2A family genes' level of expression and prognostic values were analyzed in relation to pan-cancer. We then examined the association among SLC2As expression and TME, Stemness score, clinical characteristics, immune subtypes, and drug sensitivity. We merged bioinformatics analysis techniques with up-to-date public databases. Additionally, SLC2As from the KOBAS database were subjected to enrichment analysis. Results: We discovered that SLC2As' gene expression differed significantly between normal tissues and many malignancies. A number of tumors from various databases demonstrate a relationship between prognosis and SLC2A family gene expression. For instance, SLC2A2 and SLC2A5 were associated with the overall survival (OS) of hepatocellular carcinoma. SLC2A1 was associated with the OS of lung adenocarcinoma and pancreatic adenocarcinoma. Moreover, the SLC2A family gene expression is significantly correlated with the pan-cancer stromal and immune scores, and the RNA and DNA stemness scores. Furthermore, we found that the majority of SLC2As had a strong correlation with the tumor stages in KIRC. The immunological subtypes and all members of the SLC2A gene family exhibited a substantial correlation. Moreover, pathways containing insulin resistance and adipocytokine signaling pathway may influence the progression of some cancers. Finally, there is a significant positive or negative connection between drug sensitivity and SLC2A1 expression. Conclusion: Our research highlights the significant promise of SLC2As as prognostic indicators and offers insightful approaches for upcoming exploration of SLC2As as putative therapeutic targets in malignancies. |
| first_indexed | 2024-04-24T08:12:30Z |
| format | Article |
| id | doaj.art-1ebaded9e7664c5b8cb0796a84c57ee0 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2025-03-22T03:03:24Z |
| publishDate | 2024-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-1ebaded9e7664c5b8cb0796a84c57ee02024-05-01T05:09:14ZengElsevierHeliyon2405-84402024-04-01108e29655Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targetsYating Liu0Xinyu Li1Jie Yang2Shanshan Chen3Changyu Zhu4Yijun Shi5Shoutao Dang6Weitao Zhang7Wei Li8Department of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Pediatric Dentistry, Peking University School of Stomatology, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Corresponding author. Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.Background: The major facilitator superfamily glucose transporters (GLUTs), encoded by solute carrier 2A (SLC2A) genes, mediate the transmembrane movement and uptake of glucose. To satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues. Multiple diseases, including cancer, have been associated with GLUTs. Nevertheless, not much research has been done on the functions of SLC2As in pan-cancer prognosis or their clinical treatment potential. Methods: The SLC2A family genes' level of expression and prognostic values were analyzed in relation to pan-cancer. We then examined the association among SLC2As expression and TME, Stemness score, clinical characteristics, immune subtypes, and drug sensitivity. We merged bioinformatics analysis techniques with up-to-date public databases. Additionally, SLC2As from the KOBAS database were subjected to enrichment analysis. Results: We discovered that SLC2As' gene expression differed significantly between normal tissues and many malignancies. A number of tumors from various databases demonstrate a relationship between prognosis and SLC2A family gene expression. For instance, SLC2A2 and SLC2A5 were associated with the overall survival (OS) of hepatocellular carcinoma. SLC2A1 was associated with the OS of lung adenocarcinoma and pancreatic adenocarcinoma. Moreover, the SLC2A family gene expression is significantly correlated with the pan-cancer stromal and immune scores, and the RNA and DNA stemness scores. Furthermore, we found that the majority of SLC2As had a strong correlation with the tumor stages in KIRC. The immunological subtypes and all members of the SLC2A gene family exhibited a substantial correlation. Moreover, pathways containing insulin resistance and adipocytokine signaling pathway may influence the progression of some cancers. Finally, there is a significant positive or negative connection between drug sensitivity and SLC2A1 expression. Conclusion: Our research highlights the significant promise of SLC2As as prognostic indicators and offers insightful approaches for upcoming exploration of SLC2As as putative therapeutic targets in malignancies.http://www.sciencedirect.com/science/article/pii/S240584402405686XSLC2A family genesPan-cancerPrognosisTumor microenvironmentTherapeutic targets |
| spellingShingle | Yating Liu Xinyu Li Jie Yang Shanshan Chen Changyu Zhu Yijun Shi Shoutao Dang Weitao Zhang Wei Li Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets Heliyon SLC2A family genes Pan-cancer Prognosis Tumor microenvironment Therapeutic targets |
| title | Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets |
| title_full | Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets |
| title_fullStr | Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets |
| title_full_unstemmed | Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets |
| title_short | Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets |
| title_sort | pan cancer analysis of slc2a family genes as prognostic biomarkers and therapeutic targets |
| topic | SLC2A family genes Pan-cancer Prognosis Tumor microenvironment Therapeutic targets |
| url | http://www.sciencedirect.com/science/article/pii/S240584402405686X |
| work_keys_str_mv | AT yatingliu pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT xinyuli pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT jieyang pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT shanshanchen pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT changyuzhu pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT yijunshi pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT shoutaodang pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT weitaozhang pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets AT weili pancanceranalysisofslc2afamilygenesasprognosticbiomarkersandtherapeutictargets |